Obesity in older adults is rising, and semaglutide & tirzepatide can bring significant weight loss and better heart, liver, and kidney health. Risks for older adults are muscle loss and functional decline. Policy must prioritize coverage + clinical trials for seniors to ensure

Highest Protein Foods in the World

🔑 point from AACE obesity statement Assessment of body fat % useful to Dx sarcopenic obesity in older individuals with potentially normal BMI Men >25% Women >32%

What's the difference between biological aging (body and organ clocks) vs chronological age? How can the former be useful clinically? My perspective @sciam, Q&A w/ @LaurenYoung https://t.co/CT5Sjn19wH

Writing = formalized thinking 🎯

RESEARCH Two phase 2 trials show that immunosenescence as a mechanism of resistance to immunotherapy can be overcome with the #senolytics dasatinib & quercetin in patients with head & neck squamous cell carcinoma. #cancerresearch https://t.co/z38W5VZv9d

Lithium has an essential role in the brain and is deficient early in Alzheimer’s disease, which can be recapitulated in mice and treated with a novel lithium salt that restores the physiological level, according to a paper in @Nature. https://t.co/CA4o9J3fBd

2/4) The research was conducted by the world-renowned Snyder Lab at Stanford, pioneers in “longitudinal multiomics.” This approach combines various “omes”—like the genome, proteome, transcriptome, and microbiome—to form a detailed picture of how an organism functions at the

On behalf of myself + 1st author and recently graduated geriatric cardiology fellow Dr. Marc Arcens, we would like to dedicate this to the memory of our wise and generous co-author Dr. James N. Kirkpatrick 🕯️

💥 Decision-making for older adults with advanced heart disease: a framework for balancing benefit versus futility 📄 https://t.co/sqNKvG9oGa

#10 bonus material: my framework on why we age unsuccessfully

#9 take away: @bryan_johnson's personal journey turned "cult" jolts status quo inertia and mainstream interest in a field directly affecting 8B people, now it's on us (the scientists) to not only raise flags but also raise the bar!

#8 would wealth be better spent funding these types of trials instead of n-of-1 case reports, I think so

#7 e.g. @NirBarzilaiMD's TAME trial on longevity benefits and safety of metformin (the rub: 10 years and a few million $ to test a single hypothesis) https://t.co/ogAstpQgSJ

#6 this is precisely why we need controlled trials with sufficiently large sample sizes to vet novel therapies

#5 + interacting effects of multiple concomitant therapies, muddying the waters and compounding risks

#4 rapamycin ➡️ immunosuppression ➡️ sepsis gene therapy ➡️ off target edits ➡️ cancer

#3 why not try it out? aside from the 💵 spent, the bigger risk is unexpected life threatening side effects:

#2 but... most of this research currently comes from 🐁 and 🧫 which historically often fails to translate to 🧑‍🤝‍🧑

#1 @bryan_johnson is smart. his research on longevity science is deep and valid (yes, I said it)